Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-059369
Filing Date
2026-05-12
Accepted
2026-05-12 16:06:09
Documents
127
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q xoma-20260331x10q.htm   iXBRL 10-Q 3138941
2 EX-31.1 xoma-20260331xex31d1.htm EX-31.1 14011
3 EX-31.2 xoma-20260331xex31d2.htm EX-31.2 14008
4 EX-32.1 xoma-20260331xex32d1.htm EX-32.1 8593
  Complete submission text file 0001104659-26-059369.txt   15952696

Data Files

Seq Description Document Type Size
5 EX-101.SCH xoma-20260331.xsd EX-101.SCH 137054
6 EX-101.CAL xoma-20260331_cal.xml EX-101.CAL 107138
7 EX-101.DEF xoma-20260331_def.xml EX-101.DEF 616393
8 EX-101.LAB xoma-20260331_lab.xml EX-101.LAB 971949
9 EX-101.PRE xoma-20260331_pre.xml EX-101.PRE 890534
131 EXTRACTED XBRL INSTANCE DOCUMENT xoma-20260331x10q_htm.xml XML 3013376
Mailing Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608
Business Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239
XOMA Royalty Corp (Filer) CIK: 0000791908 (see all company filings)

EIN.: 522154066 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39801 | Film No.: 26968459
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)